Lupin has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, available in 4.45 mg and 17.8 mg strengths. According to the company's official filing, the approval covers both dosage forms as bioequivalent to Wakix for the indications listed in the approved labeling. The regulatory approval represents a significant milestone for Lupin's US market expansion in the narcolepsy treatment segment, specifically targeting excessive daytime sleepiness in patients.
The regulatory approval has positioned Lupin to market its generic version of Pitolisant Tablets in the United States, providing patients with an alternative treatment option for excessive daytime sleepiness (EDS) management. This development strengthens Lupin's position in the US pharmaceutical market through expanded generic product offerings, particularly in the specialty pharmaceutical segment for sleep disorders. The approval provides Lupin with regulatory pathways to manufacture and market these generic versions in the US market, expanding the company's therapeutic portfolio in the narcolepsy treatment segment. However, Lupin shares remain technically weak despite the positive regulatory development, with the stock trading below most key moving averages and showing cautious technical indicators.
The approved formulation includes two specific strengths of Pitolisant Tablets - 4.45 mg and 17.8 mg. According to the regulatory filing, these tablets have been demonstrated to be bioequivalent to Wakix for the approved indications, ensuring therapeutic equivalence with the branded product. Wakix is a prescription medicine used to treat excessive daytime sleepiness of Harmony Biosciences, making this approval particularly significant for patients seeking affordable alternatives in the sleep disorder treatment market.
Lupin currently commands a market capitalisation of around ₹1.03 lakh crore with its 52-week high standing at ₹2,529. On the valuation front, Lupin is trading at a price-to-earnings (P/E) ratio of 18.48 and a price-to-book (P/B) ratio of 4.54. The company's technical setup shows mixed signals, with the 14-day RSI at around 34.9, indicating weak momentum though not in oversold territory. Lupin is currently trading below 7 of its 8 key simple moving averages, with the stock holding above only its 200-day SMA, suggesting near-term pressure despite the longer-term trend remaining relatively stronger.
The latest USFDA approval adds a fresh product opportunity while technical indicators remain subdued, potentially attracting increased investor attention. Foreign Institutional Investors (FIIs) have raised their stake in Lupin while mutual fund holdings declined from 16.93% to 14.84% over the same period. The approval strengthens Lupin's generic portfolio in the US market and could provide another opportunity for the company to expand its presence in the specialty and complex generics segment, positioning it well for future growth in the pharmaceutical sector.
